Opexa Therapeutics Chief Business Officer Jefferson Davis receives $635K in 2021
Opexa Therapeutics reports 2021 executive compensation
By ExecPay News
Published: April 15, 2022
Opexa Therapeutics reported fiscal year 2021 executive compensation information on April 15, 2022.
In 2021, three executives at Opexa Therapeutics received on average a compensation package of $581K, a 2% increase compared to previous year.
Average pay of disclosed executives at Opexa Therapeutics
Jefferson E. Davis, Chief Business Officer, received $635K in total. 51% of Davis' compensation, or $327K, was in salary. Davis also received $308K in option awards.
Harry Palmin, Chief Financial Officer, received a compensation package of $557K, which increased by 4% compared to previous year. 69% of the compensation package, or $382K, was in salary.
Chris Schelling, Chief Executive Officer, earned $552K in 2021, a 18% decrease compared to previous year.
Related executives
You may also like
Source: SEC filing on April 15, 2022.